title: Helicobacter pylori screening: options and challenges.
abstract: Helicobacter pylori gastritis is the most frequent infectious disease in the gastrointestinal tract. Clinical sequelae of the infection including peptic ulcer disease, sporadic gastric cancer (GC) and primary B-cell gastric lymphoma (MALT-lymphoma) may develop in up to 20% of the infected individuals. The H. pylori screen-and-treat strategy is addressed to members of communities with high GC incidence, and first-degree relatives of GC patients. For primary GC prevention, H. pylori screen-and-treat is most effective in patients without precancerous conditions. In populations at moderate risk, strategies for GC prevention need to be explored. A special clinical scenario for primary and secondary prevention of H. pylori related benign complications are patients on non-steroidal anti-inflammatory drugs and low-dose aspirin. Vaccination represents another option for eliminating H. pylori infection in the population and a new H. pylori vaccine has shown promising results. However, long-term effects with the use of vaccine are not available.
authors.affiliation: a Department of Gastroenterology, Hepatology and Infectious Diseases , Otto-von-Guericke University Hospital , Magdeburg , Germany.
authors.forename: Marino
authors.initials: M
authors.lastname: Venerito
authors.affiliation: a Department of Gastroenterology, Hepatology and Infectious Diseases , Otto-von-Guericke University Hospital , Magdeburg , Germany.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Goni
authors.affiliation: a Department of Gastroenterology, Hepatology and Infectious Diseases , Otto-von-Guericke University Hospital , Magdeburg , Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Malfertheiner
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D001431:Bacteriological Techniques; D005756:Gastritis / Q000382:microbiology / Q000517:prevention & control; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D011237:Predictive Value of Tests; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000382:microbiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines
keywords: Helicobacter pylori; gastric cancer; non-steroidal anti-inflammatory drugs; peptic ulcer disease; prevention; screening; vaccine